Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir-Lamivudine in Naïve HIV Patients with M184V Mutation
NCT05295394Phase 4Withdrawn
- Start
- May 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir, lamivudine in human immunodeficiency virus type 1 infection (HIV-1). Planned start May 2019; status: withdrawn.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05295394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295394.